10080 N WOLFE ROAD, CUPERTINO, CA
Earnings Release
Announces Pricing of $10 Million Public Offering
News, Articles of Incorporation
Material disclosure
Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Annual Report to Security Holders
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
FY 2025
Q3
Q2
Q1
FY 2024
Notice of Late Filing for Annual Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report